Farallon Capital Management’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $418K | Hold |
4,000
| – | – | ﹤0.01% | 88 |
|
|
2025
Q1 | $467K | Hold |
4,000
| – | – | ﹤0.01% | 90 |
|
|
2024
Q4 | $338K | Hold |
4,000
| – | – | ﹤0.01% | 100 |
|
|
2024
Q3 | $359K | Hold |
4,000
| – | – | ﹤0.01% | 109 |
|
|
2024
Q2 | $322K | Hold |
4,000
| – | – | ﹤0.01% | 109 |
|
|
2024
Q1 | $319K | Hold |
4,000
| – | – | ﹤0.01% | 127 |
|
|
2023
Q4 | $318K | Sell |
4,000
-121,653
| -97% | -$9.68M | ﹤0.01% | 116 |
|
|
2023
Q3 | $8.78M | Sell |
125,653
-147,147
| -54% | -$10.3M | 0.04% | 88 |
|
|
2023
Q2 | $19.6M | Buy |
+272,800
| New | +$19.6M | 0.1% | 78 |
|
|
2020
Q1 | – | Sell |
-442,222
| Closed | -$45.7M | – | 102 |
|
|
2019
Q4 | $45.7M | Buy |
442,222
+42,222
| +11% | +$4.36M | 0.31% | 55 |
|
|
2019
Q3 | $8.1M | Buy |
+400,000
| New | +$8.1M | 0.06% | 85 |
|